Related Experiment Video
Updated: Nov 16, 2025

Isolation and Identification of Extravascular Immune Cells of the Heart
Published on: August 23, 2018
Fulminant myocarditis: COVID or not COVID? Reinfection or co-infection?
Ramya Yeleti1,2, Maya Guglin3, Kashif Saleem4
1College of Osteopathic Medicine, Marion University, 3200 Cold Spring Rd, Indianapolis, IN 46222, USA.
Insights
A patient with presumed SARS-CoV-2 reinfection developed fulminant myocarditis, potentially triggered by a co-infection with Parvovirus. This case highlights a rare cause of severe heart inflammation and rapid recovery.
Area of Science:
- Cardiology
- Infectious Diseases
- Virology
Background:
- Fulminant myocarditis is a severe form of heart muscle inflammation.
- SARS-CoV-2 (the virus causing COVID-19) has been associated with cardiac complications.
- Viral co-infections can complicate the presentation and management of myocarditis.
Observation:
- A patient with a history of COVID-19 and detectable antibodies presented with fulminant myocarditis.
- Endomyocardial biopsy revealed lymphocytic myocarditis, with positive molecular testing for Parvovirus but negative for SARS-CoV-2.
- The patient experienced hemodynamic instability, requiring mechanical circulatory support with VA ECMO and Impella CP.
Findings:
- The case suggests a potential co-infection of SARS-CoV-2 and Parvovirus as a trigger for fulminant myocarditis.
- Lymphocytic myocarditis was confirmed histologically.
- Rapid recovery of left ventricular function was observed within 48 hours.
Implications:
- This case underscores the importance of considering co-infections in severe myocarditis, even with prior SARS-CoV-2 exposure.
- Parvovirus co-infection may play a role in SARS-CoV-2-associated cardiac injury.
- Prompt mechanical circulatory support and potential targeted therapy can lead to favorable outcomes in fulminant myocarditis.
Abstract:
We describe a unique case of fulminant myocarditis in a patient with presumed SARS-CoV-2 reinfection. Patient had initial infection 4 months backand had COVID-19 antibody at the time of presentation. Endomyocardial biopsy showed lymphocytic myocarditis, that is usually seen in viral myocarditis. The molecular diagnostic testing of the endomyocardial biopsy for cardiotropic viruses was positive for Parvovirus and negative for SARS-CoV-2. Authors highly suspect co-infection of SARS-CoV-2 and Parvovirus, that possibly triggered the immune cascade resulting in fulminant myocarditis. Patient was hemodynamically unstable with ventricular tachycardia and was supported on VA ECMO and Impella CP. There was impressive recovery of left ventricular function within 48 h, leading to decannulation of VA ECMO in 72 h. This unique case was written by the survivor herself.
More Related Videos
Related Concept Videos
Myocarditis I: Introduction
Myocarditis III: Medical Management
Myocarditis II: Clinical Features and Diagnostic Tests
Myocarditis IV: Nursing Management
Endocarditis II: Clinical Features of Infective Endocarditis
Endocarditis I: Introduction

